Abstract: The present invention relates to a method of determining an infection of a patient with at least one microorganism, particularly a bacterial microorganism, potentially resistant to antimicrobial drug treatment, a method of selecting a treatment of a patient suffering from an infection with at least one microorganism, particularly bacterial microorganism, and a method of determining an antimicrobial drug, e.g. antibiotic, resistance profile for at least one microorganism, particularly bacterial microorganism, as well as computer program products used in these methods.

Abstract: The invention relates to a method of determining an antimicrobial drug resistance profile for a microorganism, wherein nucleic acid sequences of the microorganism are analyzed for structural variations of the genome comprising at least a change in the genome comprising more than one base, as well as for single nucleotide polymorphisms (SNPs), as well as a method of determining an infection of a patient with a microorganism potentially resistant to antimicrobial drug treatment and a method of selecting a treatment of a patient suffering from an infection with a potentially resistant microorganism, wherein the data of the antimicrobial drug resistance profile are applied.

Abstract: The present invention relates to a method of determining markers for a disease from a patient, wherein information from epigenomics and/or the transcriptome from peripheral blood and a diseased tissue or information from epigenomics and the transcriptome from peripheral blood or a diseased tissue is used for obtaining the markers, as well as a method of determining a risk for a disease in a patient using the markers obtained thereby.

Abstract: The invention relates to novel miRNA markers useful for diagnosis or therapy of disease, in particular for neuronal disorders such as Alzheimer's Disease (AD).

Abstract: A system operating in a plurality of modes to provide an integrated analysis of molecular data, imaging data, and clinical data associated with a patient includes a multi-scale model, a molecular model, and a linking component. The multi-scale model is configured to generate one or more estimated multi-scale parameters based on the clinical data and the imaging data when the system operates in a first mode, and generate a model of organ functionality based on one or more inferred multi-scale parameters when the system operates in a second mode. The molecular model is configured to generate one or more first molecular findings based on a molecular network analysis of the molecular data, wherein the molecular model is constrained by the estimated parameters when the system operates in the first mode.

Abstract: The present invention relates to a method of determining an infection of a patient with at least one microorganism, particularly a bacterial microorganism, potentially resistant to antimicrobial drug treatment, a method of selecting a treatment of a patient suffering from an infection with at least one microorganism, particularly bacterial microorganism, and a method of determining an antimicrobial drug, e.g. antibiotic, resistance profile for at least one microorganism, particularly bacterial microorganism, as well as computer program products used in these methods.

Abstract: The disclosure relates to a method for the diagnosis of Alzheimer's disease (AD) in a patient, wherein the expression profile of miRNAs is determined in a blood sample and a comparison of the expression levels of defined miRNAs with a reference sample is carried out. The disclosure also relates to the use of the defined miRNAs as markers for the diagnosis of Alzheimer's disease and to a kit for the diagnosis of Alzheimer's disease.

Abstract: The invention relates to methods for diagnosing multiple sclerosis with miRNA markers. Diagnosis of multiple sclerosis (MS) can be challenging in patients with atypical presentations and during a first neurological deficit possibly related to inflammatory demyelination. Towards the identification of biomarkers for diagnosis of MS, a comprehensive analysis of miRNA expression patterns was obtained. Significantly deregulated miRNAs were identified, which have previously not been related to MS according to the microRNA disease database. These miRNAs could potentially serve as future diagnostic biomarkers for MS and help in diagnosis, monitoring disease activity, and evaluation of treatment responses in patients with MS.

Abstract: Genetic resistance prediction against antimicrobial drugs in microorganism using structural changes in the genome The invention relates to a method of determining an infection of a patient with at least one microorganism, particularly a bacterial microorganism, potentially resistant to antimicrobial drug treatment, a method of selecting a treatment of a patient suffering from an infection with at least one microorganism, particularly bacterial microorganism, and a method of determining structural changes of the genome of the microorganism, particularly bacterial microorganism, comprising at least one gene, as well as computer program products used in these methods.

Abstract: The invention relates to methods for diagnosing Alzheimer's Disease (AD) with miRNA markers. Diagnosis of AD Towards the identification of biomarkers for diagnosis of AD, a comprehensive analysis of miRNA expression patterns was obtained. Significantly deregulated miRNAs were identified.

Abstract: The invention relates to a method of determining an infection of a patient with Acinetobacter species potentially resistant to antimicrobial drug treatment, a method of selecting a treatment of a patient suffering from an antibiotic resistant Acinetobacter infection, and a method of determining an anti-biotic resistance profile for bacterial microorganisms of Acinetobacter species, as well as computer program products used in these methods. In an exemplary method, a sample 1, is used for molecular testing 2, and then a molecular finger-print 3 is taken. The result is then compared to a reference library 4, and the result 5 is reported.

Abstract: The invention relates to methods for diagnosing Parkinson's Disease PAD) with miRNA markers. Towards the identification of biomarkers for diagnosis of PD, a comprehensive analysis of miRNA expression patterns was obtained. Significantly deregulated miRNAs were identified.

Abstract: The invention relates to a method of diagnosis of neuromyelitis optica, in particular of differential diagnosis of neuromyelitis optica (NMO) vs. multiple sclerosis (MS) using miRNA biomarkers. These miRNAs could potentially serve as future diagnostic biomarkers for NMO and help in diagnosis, monitoring disease activity, and evaluation of treatment responses in patients with MS.

Abstract: The embodiments relate to a method of determining an antibiotic resistance profile for a bacterial microorganism and to a method of determining the resistance of a bacterial microorganism to an antibiotic drug, wherein the bacterial microorganism belongs to the species Escherichia coli (E. coli). The method includes determining a nucleic acid sequence information or determining the presence of a mutation of at least one gene.

Abstract: The invention relates to methods for diagnosing Alzheimer's Disease (AD) with miRNA markers. Diagnosis of AD Towards the identification of biomarkers for diagnosis of AD, a comprehensive analysis of miRNA expression patterns was obtained. Significantly deregulated miRNAs were identified.

Abstract: The invention relates to a method, a databank, a system and a computer program product for determining a bacterial resistance to an antibiotic drug. A data bank is provided which comprises a plurality of bacterial reference nucleic acid sequences, wherein at least some reference nucleic acid sequences are associated with a respective antibiotic drug resistance information. A comparison unit is used for comparing said bacterial nucleic acid sequence information obtained from a sample with said plurality of bacterial reference nucleic acid sequences.

Abstract: The invention relates to methods for diagnosing Parkinson's Disease PAD) with miRNA markers. Towards the identification of biomarkers for diagnosis of PD, a comprehensive analysis of miRNA expression patterns was obtained. Significantly deregulated miRNAs were identified.

Abstract: The invention relates to novel miRNA markers useful for diagnosis or therapy of disease, in particular for neuronal disorders such as Alzheimer's Disease (AD).

Abstract: The invention relates to a method and kit for enriching miRNA nucleic acids molecules of interest in a sampe by selective removal of nucleic acid species, in particular miRNA species, which are not of interest. The invention is based on the surprizing and previously unknown information that only a few individual miRNA species make up the majority of all miRNA species in a sample. Selective removal of these species prior to detection of miRNA nucleic acids molecules will improve assay time, assay sensitivity, and reproducibility.

Abstract: The invention relates to methods for diagnosing multiple sclerosis with miRNA markers. Diagnosis of multiple sclerosis (MS) can be challenging in patients with atypical presentations and during a first neurological deficit possibly related to inflammatory demyelination. Towards the identification of biomarkers for diagnosis of MS, a comprehensive analysis of miRNA expression patterns was obtained. Significantly deregulated miRNAs were identified, which have previously not been related to MS according to the microRNA disease database. These miRNAs could potentially serve as future diagnostic biomarkers for MS and help in diagnosis, monitoring disease activity, and evaluation of treatment responses in patients with MS.